176 related articles for article (PubMed ID: 20298163)
1. Molecularly targeted therapies in breast cancer bone metastases.
Clézardin P
Curr Pharm Des; 2010; 16(11):1260-1. PubMed ID: 20298163
[No Abstract] [Full Text] [Related]
2. Bisphosphonates as treatment of bone metastases.
Holen I; Coleman RE
Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
[TBL] [Abstract][Full Text] [Related]
3. Bone targeted therapy in breast cancer: present and future.
Huober J; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
[No Abstract] [Full Text] [Related]
4. Local effects of malignancy on bone.
Brown SA; Clines GA; Guise TA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in bone-targeted therapies of metastatic prostate cancer.
Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
[TBL] [Abstract][Full Text] [Related]
6. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Criscitiello C; Viale G; Gelao L; Esposito A; De Laurentiis M; De Placido S; Santangelo M; Goldhirsch A; Curigliano G
Cancer Treat Rev; 2015 Feb; 41(2):61-8. PubMed ID: 25499997
[TBL] [Abstract][Full Text] [Related]
8. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
[TBL] [Abstract][Full Text] [Related]
9. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
10. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
11. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targets for bone metastases in breast cancer.
Clézardin P
Breast Cancer Res; 2011 Apr; 13(2):207. PubMed ID: 21586099
[TBL] [Abstract][Full Text] [Related]
13. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
Vengerovskiĭ AI; Khlusov IA; Nechaev KA
Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
[TBL] [Abstract][Full Text] [Related]
14. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Vessella RL; Corey E
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
[TBL] [Abstract][Full Text] [Related]
15. Future directions of bone-targeted therapy for metastatic breast cancer.
Onishi T; Hayashi N; Theriault RL; Hortobagyi GN; Ueno NT
Nat Rev Clin Oncol; 2010 Nov; 7(11):641-51. PubMed ID: 20808302
[TBL] [Abstract][Full Text] [Related]
16. The role of RANK-ligand inhibition in cancer: the story of denosumab.
Castellano D; Sepulveda JM; García-Escobar I; Rodriguez-Antolín A; Sundlöv A; Cortes-Funes H
Oncologist; 2011; 16(2):136-45. PubMed ID: 21285392
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
18. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
19. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
20. Emerging role for bisphosphonates in cancer management.
Chlebowski RT
Breast Dis; 2011; 33(2):55-7. PubMed ID: 22142659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
